title: [Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency].
abstract: The objective of this study was to determine the risk factors of the first occurrence of Mycobacterium avium complex disease (MAC) infection among human immunodeficiency virus (HIV)-infected subjects during two different time periods: before and after the introduction of protease inhibitor (respectively, period 1: 1 January 1992 to 31 December 1995, and period 2: 1 January 1996 to 30 June 1998). This study was performed using the French Hospital Database on HIV (FHDH). Subjects were included when their CD4+ cell count was less than 100/mm3. If they did not die or develop MAC within the first 6 months after the inclusion, their follow-up had to be longer than 6 months to be included. Cox's model was used to calculated the relative hazards (RH) of MAC occurrence according to the age and time-dependent variables, such as CD4+ below 50/mm3, previous occurrence of tuberculosis, cytomegalovirus (CMV) infection and other acquired immunodeficiency syndrome (AIDS)-defining disease, nature of antiretroviral treatment and MAC prophylaxis. Among the 14,779 subjects followed during period 1, 1,710 (11.6%) had a diagnosis of MAC infection during their follow-up (incidence: 8.4 +/- 0.2 for 100 persons per year), while only 453 (4.4%) among 10,239 subjects presented this infection during period 2 (2.8 +/- 0.1 for 100 persons per year). Rifabutin regular prescription was a protective factor of MAC occurrence during period 1 (RH = 0.51 95% confidence interval (CI) = [0.37-0.69]), whereas this protective effect was not observed during period 2 (RH = 1.05 CI = [0.63-1.67]). Thus, during the HAART period, the results that we present do not indicate an interest into continuing MAC prophylaxis.
authors.affiliation: Inserm SC4, faculté de médecine Saint-Antoine, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mary-Krause
authors.forename: C
authors.initials: C
authors.lastname: Rabaud
authors.forename: M
authors.initials: M
authors.lastname: Jouan
authors.forename: M
authors.initials: M
authors.lastname: Obadia
authors.forename: A
authors.initials: A
authors.lastname: de la Blanchardière
authors.forename: F
authors.initials: F
authors.lastname: Raffi
authors.forename: T
authors.initials: T
authors.lastname: May
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006679:HIV Seropositivity / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control; D017828:Rifabutin / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D017320:HIV Protease Inhibitors; D017828:Rifabutin